Ginna G. Laport

BMT specialist, Medical oncologist, Hematologist

Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center

Blood and Marrow Transplant Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-723-0822
Learn More About the Clinic Getting Here Make An Appointment

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: University of Chicago Hospitals (1997) IL

Residency: University of Chicago Hospitals (1993) IL

Fellowship: Stanford University School of Medicine (1994) CA

Internship: University of Chicago Hospitals (1991) IL

Medical Education: University of Texas Health Science Center (1990) TX

B.A., Baylor University, Psychology (1986)

Honors & Awards

Division Teaching Award, Dept of Medicine (2003)

Administrative Appointments

Director, Clinical Research and Biostatistical Core, Blood and Marrow Transplantation, Stanford University, 2012

Chair, BMT Clinical Trials Network - NCI & NHLBI, 2012

Medical Informatics Director, Stanford Hospital -Stanford Cancer Center, 2011

ASBMT Executive Committee - Secretary, American Society of Bone Marrow Transplantation, 2011

NMDP Data Safety Monitoring Board, National Marrow Donor Program, 2009

ASH Communications Committee, American Society of Hematology, 2007

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
Fenske, T. S., Zhang, M.-J., Carreras, J., Ayala, E., Burns, L. J., & Hari, P. N. (2014). Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. Journal of clinical oncology , 32(4), 273-281.

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.
Bredeson, C., LeRademacher, J., Kato, K., DiPersio, J. F., Agura, E., & Pasquini, M. C. (2013). Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood, 122(24), 3871-3878.

Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma
Hahn, T., McCarthy, P. L., Carreras, J., Zhang, M.-J., Lazarus, H. M., & Hari, P. N. (2013). Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(12), 1740-1744.

Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.
Maziarz, R. T., Wang, Z., Zhang, M.-J., Bolwell, B. J., Chen, A. I., & Hari, P. N. (2013). Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. British journal of haematology, 162(5), 648-656.

Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
Smith, S. M., Burns, L. J., Van Besien, K., LeRademacher, J., He, W., & Hari, P. N. (2013). Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. Journal of clinical oncology , 31(25), 3100-3109.

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.
Hamadani, M., Saber, W., Ahn, K. W., Carreras, J., Cairo, M. S., & Lazarus, H. M. (2013). Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biology of blood and marrow transplantation , 19(5), 746-753.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
Storb, R., Gyurkocza, B., Storer, B. E., Sorror, M. L., Blume, K., & Sandmaier, B. M. (2013). Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. Journal of clinical oncology , 31(12), 1530-1538.

Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation
Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., & Lowsky, R. (2013). Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(2), S154-S155.

TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN
Benjamin, J., Chhabra, S., Kohrt, H., Laport, G. G., Arai, S., & Lowsky, R. (2013). TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(2), S113-S114.

Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms.
Benjamin, J., Chhabra, S., Kohrt, H. E., Laport, G. G., Arai, S., & Lowsky, R. (2012). Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms. BLOOD, 120(21).

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Bacher, U., Klyuchnikov, E., Le-Rademacher, J., Carreras, J., Armand, P., & Hari, P. N. (2012). Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. BLOOD, 120(20), 4256-4262.

Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial
Jagasia, M. H., Abonour, R., Long, G. D., Bolwell, B. J., Laport, G. G., & Waller, E. K. (2012). Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. BONE MARROW TRANSPLANTATION, 47(10), 1350-1355.

Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR
Hale, G. A., Shrestha, S., Le-Rademacher, J., Burns, L. J., Gibson, J., & Hari, P. N. (2012). Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(7), 1036-1043.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.

Tandem Transplantation for Follicular Lymphoma: The Best of Both Worlds?
Laport, G. G. (2012). Tandem Transplantation for Follicular Lymphoma: The Best of Both Worlds?. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(6), 820-821.

Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., & Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516-521.

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., & Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581-588.

Changing role of stem cell transplantation in follicular lymphoma.
Laport, G. G. (2012). Changing role of stem cell transplantation in follicular lymphoma. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2012, 417-425.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation
Sehn, L. H., Fenske, T. S., & Laport, G. G. (2012). Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(1), S82-S91.

Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells
Mueller, A. Ms., Kohrt, H. Ek., Cha, S., Laport, G., Klein, J., & Shizuru, J. A. (2012). Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(1), 125-133.

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
Krishnan, A., Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., & Maloney, D. G. (2011). Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. LANCET ONCOLOGY, 12(13), 1195-1203.

Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays - Comparison with Electrophoretic Responses in Multiple Myeloma (MM)
Hari, P., Pasquini, M. C., Logan, B. R., Stadtmauer, E. A., Krishnan, A., & Vesole, D. H. (2011). Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays - Comparison with Electrophoretic Responses in Multiple Myeloma (MM). BLOOD, 118(21), 1241-1242.

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
Sorror, M. L., Sandmaier, B. M., Storer, B. E., Franke, G. N., Laport, G. G., & Storb, R. (2011). Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 306(17), 1874-1883.

Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia
Ram, R., Storb, R., Sandmaier, B. M., Maloney, D. G., Woolfrey, A., & Georges, G. E. (2011). Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 96(8), 1113-1120.

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response
Tomblyn, M. R., Ewell, M., Bredeson, C., Kahl, B. S., Goodman, S. A., & Laport, G. G. (2011). Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(7), 1051-1057.

LONG-TERM FOLLOW-UP OF METASTATIC BREAST CANCER PATIENTS RECEIVING HIGHLY PURIFIED AUTOLOGOUS CD34+THY-1+HEMATOPOIETIC STEM CELLS AFTER HIGH-DOSE CHEMOTHERAPY
Mueller, A. Ms., Kohrt, H. Ek., Laport, G. G., Negrin, R. S., Cha, S., & Shizuru, J. A. (2011). LONG-TERM FOLLOW-UP OF METASTATIC BREAST CANCER PATIENTS RECEIVING HIGHLY PURIFIED AUTOLOGOUS CD34+THY-1+HEMATOPOIETIC STEM CELLS AFTER HIGH-DOSE CHEMOTHERAPY. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(2), S198-S198.

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., & Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192-199.

Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy
Laport, G. G. (2010). Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy. CURRENT OPINION IN ONCOLOGY, 22(5), 409-413.

Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.

Noninvasive Prediction of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling.
Li, L., Kohrt, H., Heish, S., Alizadeh, A., Laport, G., & Sarwal, M. (2010). Noninvasive Prediction of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling. AMERICAN JOURNAL OF TRANSPLANTATION, 10, 483-483.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review
Oliansky, D. M., Gordon, L. I., King, J., Laport, G., Leonard, J. P., & Hahn, T. (2010). The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(4), 443-468.

Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., & Laport, G. G. (2010). Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. BONE MARROW TRANSPLANTATION, 45(2), 303-309.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.

Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies
Naik, S. G., Negrin, R., Laport, G., Miklos, D., Shizuru, J., & Johnston, L. (2009). Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies. JOURNAL OF CLINICAL ONCOLOGY, 27(15).

Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity.
Kohrt, H., Turnbull, B., Laport, G., Miklos, D., Shizuru, J., & Lowsky, R. (2008). Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity. BLOOD, 112(11), 1136-1137.

Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd
Arai, S., Sahaf, B., Jones, C., Zhender, J., Lowsky, R., & Miklos, D. (2008). Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd. BLOOD, 112(11), 178-178.

Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma.
Arai, S., Letsinger, R., Johnston, L., Laport, G., Lowsky, R., & Horning, S. (2008). Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma. BLOOD, 112(11), 765-766.

Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen
Laport, G. G., Alvarnas, J. C., Palmer, J. M., Snyder, D. S., Slovak, M. L., & Forman, S. J. (2008). Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. BLOOD, 112(3), 903-909.

Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: The Stanford experience
Chen, A. I., McMillan, A., Neprin, R. S., Horning, S. J., & Laport, G. G. (2008). Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: The Stanford experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14(7), 741-747.

Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with follicular non-hodgkins lymphoma (FL) beyond first complete response or first partial response
Laport, G., Bredeson, C., Tomblyn, M. R., Kahl, B. S., Goodman, S. A., & Negrin, R. S. (2008). Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with follicular non-hodgkins lymphoma (FL) beyond first complete response or first partial response. JOURNAL OF CLINICAL ONCOLOGY, 26(15).

Reduced-intensity conditioning follow by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders
Laport, G. G., Sandmaier, B. M., Storer, B. E., Scott, B. L., Stuart, M. J., & Storb, R. F. (2008). Reduced-intensity conditioning follow by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14(2), 246-255.

Controversies in lymphoma: The role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma
Dreger, P., & Laport, G. G. (2008). Controversies in lymphoma: The role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14(1), 100-107.

Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review
Laport, G. G. (2008). Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review. LEUKEMIA & LYMPHOMA, 49(10), 1854-1859.

Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy
Arai, S., Sheehan, K., Moore, S., Laport, G., Johnston, L., & Negrin, R. (2007). Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy. BLOOD, 110(11), 179A-179A.

Mantle cell lymphoma in first complete remission
Laport, G. G. (2007). Mantle cell lymphoma in first complete remission. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 13(9), 1118-1119.

Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin (TLI-ATG) nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD
Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., & Miklos, D. (2007). Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin (TLI-ATG) nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 13(2), 103-103.

Rituximab infusion two months after nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD.
Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., & Miklos, D. (2006). Rituximab infusion two months after nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD. BLOOD, 108(11), 823A-823A.

Clinical outcomes following allogeneic hematopoietic cell transplantation (HCT) using nonmyeloablative host conditioning with total lymphoid irradiation and anti-thymocyte globulin confirm a low incidence of graft versus host disease (GVHD) and retained graft anti-tumor activity.
Lowsky, R., Stockert-Goldstein, K., Laport, G., Miklos, D., Arai, S., & Strober, S. (2006). Clinical outcomes following allogeneic hematopoietic cell transplantation (HCT) using nonmyeloablative host conditioning with total lymphoid irradiation and anti-thymocyte globulin confirm a low incidence of graft versus host disease (GVHD) and retained graft anti-tumor activity. BLOOD, 108(11), 182A-182A.

Cytokine induced killer (CIK) cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation.
Laport, G. G., Sheehan, K., Lowsky, R., Shizuru, J. A., Stockerl-Goldstein, K., & Negrin, R. S. (2006). Cytokine induced killer (CIK) cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation. BLOOD, 108(11), 126A-126A.

High dose therapy and autologous hematopoietic cell transplantation for primary refractory diffuse large cell non-Hodgkin's lymphoma.
Cao, T. M., Stockerl-Goldstein, K. E., Cao, P. D., Laport, G. G., Sheehan, K., & Lowsky, R. (2006). High dose therapy and autologous hematopoietic cell transplantation for primary refractory diffuse large cell non-Hodgkin's lymphoma. BLOOD, 108(11), 462B-463B.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., & Stockerl-Goldstein, K. E. (2006). High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(7), 703-711.

The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma
Laport, G. G. (2006). The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(1), 59-65.

Haploidentical non-myeloablative allogeneic hematopoietic cell transplantation (HCT) using total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) conditioning protects against acute graft versus host disease (GVHD)
Lowsky, R., Heydari, K., Sahaf, B., Shizuru, J., Laport, G., & Strober, S. (2005). Haploidentical non-myeloablative allogeneic hematopoietic cell transplantation (HCT) using total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) conditioning protects against acute graft versus host disease (GVHD). BLOOD, 106(11), 814A-815A.

Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma
Tong, J., Laport, G., & Lowsky, R. (2005). Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. BONE MARROW TRANSPLANTATION, 36(8), 739-740.

Protective conditioning for acute graft-versus-host disease
Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., & Strober, S. (2005). Protective conditioning for acute graft-versus-host disease. NEW ENGLAND JOURNAL OF MEDICINE, 353(13), 1321-1331.

A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stream cell transplantation for recurrent or refractory Hodgkin's lymphoma.
Arai, S., Negrin, R., Blume, K., Johnston, L., Laport, G., & Horning, S. (2005). A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stream cell transplantation for recurrent or refractory Hodgkin's lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 597S-597S.

Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., & Lowsky, R. (2005). Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose. BLOOD, 105(6), 2300-2306.

CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., & Lowsky, R. (2005). CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. EXPERIMENTAL HEMATOLOGY, 33(3), 279-285.

Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell transplantation for malignant diseases is affected by CD8(+) T-cell dose.
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., & Lowsky, R. (2004). Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell transplantation for malignant diseases is affected by CD8(+) T-cell dose. BLOOD, 104(11), 56A-56A.

Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation
Kebriaei, P., Winter, J. N., Laport, G. G., Le Beau, M. M., Dewald, G., & Larson, R. A. (2004). Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. LEUKEMIA RESEARCH, 28(5), 537-540.

Non-myeloablative conditioning with total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) for allogeneic hematopoietic cell transplantation (HCT) results in high levels of regulatory natural killer T cells and low incidences of acute GVHD and tumor relapse.
Lowsky, R., Jones, S. D., Mitra, S., Shizuru, J. A., Laport, G. G., & Strober, S. (2003). Non-myeloablative conditioning with total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) for allogeneic hematopoietic cell transplantation (HCT) results in high levels of regulatory natural killer T cells and low incidences of acute GVHD and tumor relapse. BLOOD, 102(11), 152A-153A.

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34(+)-selected hernatopoietic cell transplantation
Laport, G. G., Levine, B. L., Stadtmauer, E. A., Schuster, S. J., Luger, S. I., & June, C. H. (2003). Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34(+)-selected hernatopoietic cell transplantation. BLOOD, 102(6), 2004-2013.

Nonmyeloablative allogeneic stem cell transplantation for acute leukemia.
Laport, G. G. (2003). Nonmyeloablative allogeneic stem cell transplantation for acute leukemia. Current hematology reports, 2(1), 49-56.

A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer
Laport, G. G., Fleming, G. F., Waggoner, S., Zimmerman, T. M., Grinblatt, D. L., & Williams, S. F. (2001). A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. BONE MARROW TRANSPLANTATION, 27(7), 677-681.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation
Porter, D. L., Luger, S. M., Duffy, K. M., Stadtmauer, E. A., Laport, G., & Antin, J. H. (2001). Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(4), 230-238.

Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation
Mathias, C., Mick, R., Grupp, S., Duffy, K., Harris, F., & Porter, D. L. (2000). Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 9(3), 393-400.

A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies
Sobecks, R. M., Daugherty, C. K., Hallahan, D. E., Laport, G. F., Wagner, N. D., & Larson, R. A. (2000). A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies. BONE MARROW TRANSPLANTATION, 25(8), 807-813.

Transplantation with low-density autologous PBSC prepared with BDS60 for women with stage II, III and IV breast cancer
Laport, G. G., Valone, F. H., Zimmerman, T. M., Grinblatt, D. L., Van Vlasselaer, P., & Williams, S. F. (2000). Transplantation with low-density autologous PBSC prepared with BDS60 for women with stage II, III and IV breast cancer. CYTOTHERAPY, 2(3), 179-185.

The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma
Laport, G. F., & Williams, S. F. (1998). The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. SEMINARS IN ONCOLOGY, 25(4), 503-517.

High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience
Laport, G. F., Grad, G., Grinblatt, D. L., Bitran, J. D., & Williams, S. F. (1998). High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. BONE MARROW TRANSPLANTATION, 21(2), 127-132.

Treatment of adult acute lymphoblastic leukemia
Laport, G. F., & Larson, R. A. (1997). Treatment of adult acute lymphoblastic leukemia. SEMINARS IN ONCOLOGY, 24(1), 70-82.